Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-09-04
2007-09-04
O'Hara, Eileen B. (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S252300, C435S363000, C536S023500, C530S350000
Reexamination Certificate
active
09525998
ABSTRACT:
The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
REFERENCES:
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4560649 (1985-12-01), Saxena et al.
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4675285 (1987-06-01), Clark et al.
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4931544 (1990-06-01), Katre et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4966888 (1990-10-01), Saxena et al.
patent: 5089261 (1992-02-01), Nitecki et al.
patent: 5116964 (1992-05-01), Capon
patent: 5136021 (1992-08-01), Dembinski et al.
patent: 5153265 (1992-10-01), Shandle et al.
patent: 5162430 (1992-11-01), Rhee et al.
patent: 5214131 (1993-05-01), Sano et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5344915 (1994-09-01), LeMaire et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5633145 (1997-05-01), Feldmann et al.
patent: 5695953 (1997-12-01), Wallach et al.
patent: 5712155 (1998-01-01), Smith et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5811261 (1998-09-01), Wallach et al.
patent: 5863786 (1999-01-01), Feldmann et al.
patent: 6294352 (2001-09-01), Hauptmann et al.
patent: 03913101.7 (1989-04-01), None
patent: 03920282.8 (1989-06-01), None
patent: 03910323 (1989-10-01), None
patent: 0154316 (1985-09-01), None
patent: 0162699 (1985-11-01), None
patent: 0247860 (1987-12-01), None
patent: 0259863 (1988-03-01), None
patent: 0308378 (1989-03-01), None
patent: 0154316 (1989-09-01), None
patent: 0334165 (1989-09-01), None
patent: 0225579 (1989-11-01), None
patent: 0393438 (1990-10-01), None
patent: 0398327 (1990-11-01), None
patent: 0412486 (1991-02-01), None
patent: 0417563 (1991-03-01), None
patent: 0418014 (1991-03-01), None
patent: 0422339 (1991-04-01), None
patent: 0433900 (1991-06-01), None
patent: 0512528 (1992-11-01), None
patent: 0526905 (1993-02-01), None
patent: 2218101 (1989-11-01), None
patent: 2246569 (1992-02-01), None
patent: WO92/01002 (1990-02-01), None
patent: WO90/13575 (1990-11-01), None
patent: WO91/03553 (1991-03-01), None
patent: WO92/07076 (1992-04-01), None
patent: WO92/13095 (1992-08-01), None
patent: WO92/15682 (1992-09-01), None
patent: WO92/16221 (1992-10-01), None
patent: WO93/01474 (1993-01-01), None
patent: WO94/06476 (1994-03-01), None
US 5,843,791, 12/1998, Hauptmann et al. (withdrawn)
Wang et al., Nuc. Acids Res. 27: 4609-4618, 1999; p. 4617.
Kaufman et al, Blood 94: 3178-3184, 1999.
Wigley et al. Reprod Fert Dev 6: 585-588, 1994.
Campbell et al. Theriology 47(1): 63-72, 1997.
Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001.
Aggarwal et al., “Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon,” Nature 318:665-67 (1985).
Baglioni et al., “Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition,” J. Biol. Chem. 260:13395-97 (1985).
Bakouche et al., “Plasma membrane-associated tumor necrosis factor. A non-integral membrane protein possibly bound to its own receptor,” J. Immunol. 140:1142-47 (1988).
Beutler et al., “Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin,” Science 229:869-71 (1985).
Binkert et al., “Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2),” EMBO J. 8:2497-502 (1989).
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science 247:1306-10 (1990).
Brennan et al., “Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis,” Lancet 2:244-47 (1989).
Brockhaus, M. et al., Proc. Natl. Acad. Sci. USA 87:3127-3131 (1990).
Capaldi et al., “Changes in order of migration of polypeptides in complex III and cytochrome C oxidase under different conditions of SDS polyacrylamide gel electrophoresis,” Biochem. Biophys. Res. Commun. 74:425-33 (1977).
Carlino et al., Use of a Sensitive Receptor Binding Assay to Discriminate Between Full-Length and Truncated Human Recombinant TNF.
Colletti et al., “The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion,” Transplantation 49:268-72 (1990).
Creasy, A. et al., Proc. Natl. Acad. Sci. USA 84:3293-3297 (1987).
Dayer et al., “Purification and Characterization of Human Tumor Necrosis Factor a Inhibitor,” Chemical Abstracts 113(38760n):454 (1990).
Engelmann et al., “A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity,” J. Biol. Chem. 264:11974-80 (1989).
Engelmann et al., “Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity,,” J. Biol. Chem. 265:14497-504 (1990).
Espevik et al., “Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor,” J. Exp. Med. 171:415-26 (1990).
Evans, “The steroid and thyroid hormone receptor superfamily,” Science 240:889-95 (1988).
Frohman et al., “Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer,” Proc. Natl. Acad. Sci. U. S. A. 85:8998-9002 (1988).
Gatanaga et al., Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin . . . , Proc. Natl. Acad. Sci. USA 87:8781-8784 (1990).
Goodson et al., “Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site,” BioTechnology 8:343-346 (1990).
Goodwin et al., “Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor,” Mol. Cell. Biol. 11:3020-26 (1991).
Gray et al., “Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein,” Proc. Natl. Acad. Sci. U. S. A. 87:7380-84 (1990).
Grizzard et al., “Affinity-labeled somatomedin-C receptors and binding proteins from the human fetus,” J. Clin. Endocrinol. Metab. 58:535-43 (1984).
Hale et al., “Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed inE. coli,” J. Cell Biochem. Suppl. 15F:113(1991).
Hass et al., “Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts,” J. Biol. Chem. 260:12214-18 (1985).
Hatakeyama et al., “Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's,”
Hauptmann Rudolf
Himmler Adolf
Maurer-Fogy Ingrid
Stratowa Christian
Amgen Inc.
O'Hara Eileen B.
LandOfFree
TNF receptors, TNF binding proteins and DNAs coding for them does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF receptors, TNF binding proteins and DNAs coding for them, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF receptors, TNF binding proteins and DNAs coding for them will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775605